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Circulating Acylcarnitines and the Failing Heart’s
Energetic Signature*J. Eduardo Rame, MD, MPHILI n this issue of the Journal, Ahmad et al. (1) reporton an important novel metabolic phenotypeassayed in peripheral blood that is associated
with human heart failure (HF). Their study identiﬁed
circulating metabolites that hold prognostic and
potentially mechanistic insights toward a more com-
plete understanding of HF disease progression. These
metabolites, measured with high precision in plasma
using tandem mass spectroscopy with the addition
of internal standards, not only provided prognostic
information, but did so in a HF stage-dependent
manner.SEE PAGE 291The authors should be congratulated on the study
design: ﬁrst identifying the metabolite groups that
were associated with peak oxygen consumption ob-
tained during baseline testing for the HF-ACTION
(Heart Failure: A Controlled Trial Investigating Out-
comes of Exercise Training) trial, then subsequently
ﬁnding the circulating metabolites associated with
the outcome of all-cause mortality and hospitaliza-
tion adjudicated within the trial. Finally, in an inde-
pendent cohort of advanced HF patients who
required mechanical assist device support, the in-
vestigators found increased plasma metabolite levels*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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HeartWare Inc.in those subjects with American College of Cardiology/
American Heart Association stage D HF compared with
those with chronic, less advanced HF. These levels
returned to those associated with a less severe
phenotype with the reversal and restaging of HF that
has been reported with left ventricular assist device
therapy (2,3).
What are these metabolites of interest and how
signiﬁcant are they in elucidating the metabolic
adaptations taking place in human HF? The
metabolites—long-chain acylcarnitines—represent an
important subgroup of lipids for fatty acid oxidation
in muscle and liver. Clinically, they are measured to
screen for and diagnose inborn errors of fatty acid
oxidation and organic acid metabolism (4). Thus,
altered circulating levels of an acylcarnitine species
may reﬂect a speciﬁc metabolic deﬁcit, which, if
corrected, would allow for the metabolic ﬂux to be
restored within a certain pathway. The essential
questions to ask here: what metabolic alteration in
human HF produces the increased circulating long-
chain acylcarnitines, and where are these metabolite
species identiﬁed by Ahmad et al. (1) originating
from?
Recent work from several groups has contributed
to the characterization of a “metabolic signature” in
human HF. The components described thus far
include: 1) systemic and myocardial insulin resis-
tance; 2) weight loss resulting in cachexia; 3) a
metabolic switch from the predominant fatty acid
oxidation for substrate utilization to generate acetyl-
coenzyme A (CoA) to glucose oxidation in the failing
myocardium; and 4) mitochondrial dysfunction in the
process of downstream substrate oxidation (Krebs
cycle and oxidative phosphorylation). This new paper
by Ahmad et al. (1) overlies another facet of the failing
metabolic phenotype: increased circulating acylcar-
nitines, especially those derived from the most
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301abundant dietary fatty acids (C16, C18) common with
worsening stages of HF.
Whereas the authors provided strong evidence for
this novel metabolic phenotype associated with HF
progression, they proposed a mechanism that ulti-
mately may not prove to be true. To wit, the authors
suggested that the increased signal for peripheral
long-chain acylcarnitines is derived from a failing
heart that is not capable of utilizing this energetic
lipid pool due to deﬁciency in the carnitine palmitoyl
transferase system (CPT1/CPT2) and carnitine acyl-
carnitine translocase systems of acyl-CoA transport.
However, it is not fully established that these systems
of fatty acid oxidation are necessarily decreased in
nondiabetic, lean HF patients, especially in the more
advanced stage associated with worse outcomes and
requiring mechanical assist device support. It may be
the case that the rate of fatty acid oxidation exceeds
the ﬂux of the tricarboxylic acid (Krebs) cycle, andFIGURE 1 The Metabolic Progression of Human Heart Failure
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Disease progression in human heart failure is characterized by activation
peptide systems. This, in turn, leads to the sustained hydrolysis of trigly
triglyceride lipases, resulting in loss of adipocyte mass and suppression
nonesteriﬁed fatty acids (NEFAs), known to be increased in heart failure
When the rates of FAO exceed the capacity for downstream substrate o
ketogenesis and, most likely, active acylcarnitine efﬂux into the periphery
the various stages of human heart failure, may be responsible for induc
with resulting increased utilization of beta-hydroxybutyrate (b-OHB) for
acylcarnitines, known to be associated with and possibly inﬂict insulin r
of human heart failure. ANP ¼ atrial natriuretic peptide; BNP ¼ B-typethe feedback from this leads to decreased processing
of acylcarnitines, in turn leading to effective efﬂux of
acylcarnitines into the plasma pool (5–7). Some
studies have found that the intramyocardial acylcar-
nitine pool is decreased in HF (7,8), thus refuting this
as a possible mechanism and the heart as a possible
source of efﬂuxed long-chain acylcarnitines into the
peripheral blood. As suggested by the authors, not
only is the source of the circulating long-chain acyl-
carnitines of interest in determining the active sites
of lipid turnover in HF, but the peripheral acylcarni-
tine excess may affect the state of systemic insulin
resistance via mechanisms yet to be determined, but
that most likely involve chronic neurohormonal
activation (9).
Because our group and others have identiﬁed
increased circulating nonesteriﬁed fatty acids and
ketones (7,10) to be characteristic of the peripheral
milieu in advanced nondiabetic human HF, anAdipocytes
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of neurohormonal pathways, including adrenergic and natriuretic
cerides through the activation of hormone-sensitive and adipocyte
of leptin release from the fat cells. The release into the periphery of
, is handled by the liver, with increasing fatty acid oxidation (FAO).
xidation via the Krebs cycle, this will result in a program of hepatic
. This increase in circulating ketones, which has also been observed in
ing metabolic reprogramming of the end-stage failing human heart
fuel. The physiological consequences of increased circulating
esistance, will require further investigation in the chronic syndrome
natriuretic peptide.
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302alternative mechanism could explain the key ﬁnding
by Ahmad et al. (1) of increased long-chain acylcar-
nitines in the plasma (Figure 1). Here, the sustained
lipolysis due to chronic activation of both the sym-
pathetic and natriuretic peptide systems in HF (11,12)
results in overload of peripheral free fatty acids,
while the peripheral adipocyte mass is depleted in a
cachectic phenotype. The free fatty acid overload is
handled primarily by the liver, where increased fatty
acid oxidation may exceed downstream pathways to
further oxidize acetyl-CoA, resulting in a state of
active hepatic ketogenesis and acylcarnitine efﬂux to
the plasma compartment to prevent CoA trapping and
hepatic lipotoxicity (13). As our recent data suggest
that the failing myocardium in end-stage HF utilizes
ketones that are readily available from the periphery(14), a more complete and consistent signature of
metabolic adaptations in chronic human HF may
ﬁnally be emerging (Figure 1).
The strong evidence provided in this new paper
that the long-chain acylcarnitine pool may be an
important intermediate phenotype is central to this
understanding of the metabolic stages in human HF
and may allow for the development of therapeutic
interventions that heretofore have not been consid-
ered for restaging this chronic syndrome in humans.
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